FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:884-885 September 21, 2000 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rascol, O. PubMed Citation

To the Editor: Rascol et al. (May 18 issue)¹ summarize the results of their study by stating that Parkinson's disease is best managed with ropinirole alone as the initial treatment, with levodopa used as a supplemental, second step if necessary. This recommendation is based on their finding that the risk of dyskinesias (medication-induced chorea) is lower with ropinirole.

If a reduced risk of dyskinesia is to be the basis for making a recommendation with such broad implications, then the magnitude of the problem must warrant this concern. We reviewed the medical records of 350 randomly chosen patients with Parkinson's disease . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Van Gerpen, J. A., Kumar, N., Bower, J. H., Weigand, S., Ahlskog, J. E. (2006). Levodopa-Associated Dyskinesia Risk Among Parkinson Disease Patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 63: 205-209 [Abstract] [Full Text]  
• Albin, R. L., Frey, K. A. (2003). Initial agonist treatment of Parkinson disease: A critique. Neurology 60: 390-394 [Abstract] [Full Text]  
• Lees, A. J., Katzenschlager, R., Head, J., Ben-Shlomo, Y. (2001). Ten-year follow-up of three different initial treatments in de-novo PD: A randomized trial. Neurology 57: 1687-1694 [Abstract] [Full Text]